This
page
is
part
of
the
FHIR
Specification
(v1.8.0:
STU
3
Draft).
The
current
version
which
supercedes
this
version
is
5.0.0
.
For
a
full
list
of
available
versions,
see
the
Directory
of
published
versions
.
Page
versions:
R4
R3
This code system (http://hl7.org/fhir/v3/ObservationInterpretation) is defined as part of HL7 v3. Related FHIR content: Observation Interpretation Codes .
Summary
| Defining URL: |
http://hl7.org/fhir/v3/ObservationInterpretation
|
| Name: | v3 Code System ObservationInterpretation |
| Definition: | One or more codes specifying a rough qualitative interpretation of the observation, such as "normal", "abnormal", "below normal", "change up", "resistant", "susceptible", etc. OpenIssue: Description copied from Concept Domain of same name. Must be verified. Note also that this might be identical to the V2 code system of interpretation codes (formerly Abnormal Flags in older versions). |
| OID: | 2.16.840.1.113883.5.83 (for OID based terminology systems) |
| Source Resource | XML / JSON |
This Code system is used in the following value sets:
Release Date: 2016-11-11
| Level | Code | Display | Definition |
| 1 | (_GeneticObservationInterpretation) Abstract |
Codes
that
specify
interpretation
of
genetic
analysis,
such
as
"positive",
"negative",
"carrier",
"responsive",
etc.
|
|
| 2 | CAR | Carrier |
The
patient
is
considered
as
carrier
based
on
the
testing
results.
A
carrier
is
an
individual
who
carries
an
altered
form
of
a
gene
which
can
lead
to
having
a
child
or
offspring
in
future
generations
with
a
genetic
disorder.
|
| 2 | Carrier Deprecated | Carrier |
The
patient
is
considered
as
carrier
based
on
the
testing
results.
A
carrier
is
an
individual
who
carries
an
altered
form
of
a
gene
which
can
lead
to
having
a
child
or
offspring
in
future
generations
with
a
genetic
disorder.
Deprecation Comment: This code is currently the same string as the print name for this concept and is inconsistent with the conventions being used for the other codes in the coding system, as it is a full word with initial capitalization, rather than an all upper case mnemonic. The recommendation from OO is to deprecate the code "Carrier" and to add "CAR" as the new active code representation for this concept. |
| 1 | (_ObservationInterpretationChange) Abstract |
Interpretations
of
change
of
quantity
and/or
severity.
At
most
one
of
B
or
W
and
one
of
U
or
D
allowed.
|
|
| 2 | B | Better |
The
current
result
or
observation
value
has
improved
compared
to
the
previous
result
or
observation
value
(the
change
is
significant
as
defined
in
the
respective
test
procedure).
[Note: This can be applied to quantitative or qualitative observations.] |
| 2 | D | Significant change down |
The
current
result
has
decreased
from
the
previous
result
for
a
quantitative
observation
(the
change
is
significant
as
defined
in
the
respective
test
procedure).
|
| 2 | U | Significant change up |
The
current
result
has
increased
from
the
previous
result
for
a
quantitative
observation
(the
change
is
significant
as
defined
in
the
respective
test
procedure).
|
| 2 | W | Worse |
The
current
result
or
observation
value
has
degraded
compared
to
the
previous
result
or
observation
value
(the
change
is
significant
as
defined
in
the
respective
test
procedure).
[Note: This can be applied to quantitative or qualitative observations.] |
| 1 | (_ObservationInterpretationExceptions) Abstract |
Technical
exceptions
resulting
in
the
inability
to
provide
an
interpretation.
At
most
one
allowed.
Does
not
imply
normality
or
severity.
|
|
| 2 | < | Off scale low |
The
result
is
below
the
minimum
detection
limit
(the
test
procedure
or
equipment
is
the
limiting
factor).
Synonyms: Below analytical limit, low off scale. |
| 2 | > | Off scale high |
The
result
is
above
the
maximum
quantifiable
limit
(the
test
procedure
or
equipment
is
the
limiting
factor).
Synonyms: Above analytical limit, high off scale. |
| 2 | AC Deprecated | Anti-complementary substances present |
A
valid
result
cannot
be
obtained
for
the
specified
component
/
analyte
due
to
the
presence
of
anti-complementary
substances
in
the
sample.
Deprecation Comment: This code is being deprecated to match the status in V2 Table 0078 "Interpretation Codes. |
| 2 | IE | Insufficient evidence |
There
is
insufficient
evidence
that
the
species
in
question
is
a
good
target
for
therapy
with
the
drug.
A
categorical
interpretation
is
not
possible.
[Note: A MIC with "IE" and/or a comment may be reported (without an accompanying S, I or R-categorization).] |
| 2 | QCF Deprecated | Quality control failure |
A
result
cannot
be
considered
valid
for
the
specified
component
/
analyte
or
organism
due
to
failure
in
the
quality
control
testing
component.
Deprecation Comment: This code is being deprecated to match the status in V2 Table 0078 "Interpretation Codes. |
| 2 | TOX Deprecated | Cytotoxic substance present |
A
valid
result
cannot
be
obtained
for
the
specified
organism
or
cell
line
due
to
the
presence
of
cytotoxic
substances
in
the
sample
or
culture.
Deprecation Comment: This code is being deprecated to match the status in V2 Table 0078 "Interpretation Codes. |
| 1 | (_ObservationInterpretationNormality) Abstract |
Interpretation
of
normality
or
degree
of
abnormality
(including
critical
or
"alert"
level).
Concepts
in
this
category
are
mutually
exclusive,
i.e.,
at
most
one
is
allowed.
|
|
| 2 | A | Abnormal |
The
result
or
observation
value
is
outside
the
reference
range
or
expected
norm
(as
defined
for
the
respective
test
procedure).
[Note: Typically applies to non-numeric results.] |
| 3 | AA | Critical abnormal |
The
result
or
observation
value
is
outside
a
reference
range
or
expected
norm
at
a
level
at
which
immediate
action
should
be
considered
for
patient
safety
(as
defined
for
the
respective
test
procedure).
[Note: Typically applies to non-numeric results. Analogous to critical/panic limits for numeric results.] |
| 4 | HH | Critical high |
The
result
for
a
quantitative
observation
is
above
a
reference
level
at
which
immediate
action
should
be
considered
for
patient
safety
(as
defined
for
the
respective
test
procedure).
Synonym: Above upper panic limits. |
| 4 | LL | Critical low |
The
result
for
a
quantitative
observation
is
below
a
reference
level
at
which
immediate
action
should
be
considered
for
patient
safety
(as
defined
for
the
respective
test
procedure).
Synonym: Below lower panic limits. |
| 3 | H | High |
The
result
for
a
quantitative
observation
is
above
the
upper
limit
of
the
reference
range
(as
defined
for
the
respective
test
procedure).
Synonym: Above high normal |
| 4 | H> Deprecated | Significantly high |
A
test
result
that
is
significantly
higher
than
the
reference
(normal)
or
therapeutic
interval,
but
has
not
reached
the
critically
high
value
and
might
need
special
attention,
as
defined
by
the
laboratory
or
the
clinician.[Note:
This
level
is
situated
between
'H'
and
'HH'.]
Deprecation Comment: The code 'H>' is being deprecated in order to align with the use of the code 'HU' for "Very high" in V2 Table 0078 "Interpretation Codes". [Note: The use of code 'H>' is non-preferred, as this code is deprecated and on track to be retired; use code 'HU' instead. |
| 5 | HH | ||
| 4 | HU | Significantly high |
A
test
result
that
is
significantly
higher
than
the
reference
(normal)
or
therapeutic
interval,
but
has
not
reached
the
critically
high
value
and
might
need
special
attention,
as
defined
by
the
laboratory
or
the
clinician.
|
| 5 | HH | ||
| 3 | L | Low |
The
result
for
a
quantitative
observation
is
below
the
lower
limit
of
the
reference
range
(as
defined
for
the
respective
test
procedure).
Synonym: Below low normal |
| 4 | L< Deprecated | Significantly low |
A
test
result
that
is
significantly
lower
than
the
reference
(normal)
or
therapeutic
interval,
but
has
not
reached
the
critically
low
value
and
might
need
special
attention,
as
defined
by
the
laboratory
or
the
clinician.[Note:
This
level
is
situated
between
'L'
and
'LL'.]
Deprecation Comment: The code 'L<' is being deprecated in order to align with the use of the code 'LU' for "Very low" in V2 Table 0078 "Interpretation Codes". [Note: The use of code 'L<' is non-preferred, as this code is deprecated and on track to be retired; use code 'LU' instead. |
| 5 | LL | ||
| 4 | LU | Significantly low |
A
test
result
that
is
significantly
lower
than
the
reference
(normal)
or
therapeutic
interval,
but
has
not
reached
the
critically
low
value
and
might
need
special
attention,
as
defined
by
the
laboratory
or
the
clinician.
|
| 5 | LL | ||
| 2 | N | Normal |
The
result
or
observation
value
is
within
the
reference
range
or
expected
norm
(as
defined
for
the
respective
test
procedure).
[Note: Applies to numeric or non-numeric results.] |
| 1 | (_ObservationInterpretationSusceptibility) Abstract |
Interpretations
of
anti-microbial
susceptibility
testing
results
(microbiology).
At
most
one
allowed.
|
|
| 2 | IE | ||
| 2 | I | Intermediate |
Bacterial
strain
inhibited
in
vitro
by
a
concentration
of
an
antimicrobial
agent
that
is
associated
with
uncertain
therapeutic
effect.
Reference:
CLSI
(http://www.clsi.org/Content/NavigationMenu/Resources/HarmonizedTerminologyDatabase/Harmonized_Terminolo.htm)
Projects:
ISO
20776-1,
ISO
20776-2
[Note 1: Bacterial strains are categorized as intermediate by applying the appropriate breakpoints in a defined phenotypic test system.] [Note 2: This class of susceptibility implies that an infection due to the isolate can be appropriately treated in body sites where the drugs are physiologically concentrated or when a high dosage of drug can be used.] [Note 3: This class also indicates a "buffer zone," to prevent small, uncontrolled, technical factors from causing major discrepancies in interpretations.] [Note 4: These breakpoints can be altered due to changes in circumstances (e.g., changes in commonly used drug dosages, emergence of new resistance mechanisms).] |
| 2 | MS Deprecated | moderately susceptible |
The
patient
is
considered
as
carrier
based
on
the
testing
results.
A
carrier
is
an
individual
who
carries
an
altered
form
of
a
gene
which
can
lead
to
having
a
child
or
offspring
in
future
generations
with
a
genetic
disorder.
Deprecation Comment: This antimicrobial susceptibility test interpretation concept is recommended by OO to be deprecated as it is no longer recommended for use in susceptibility testing by CLSI (reference CLSI document M100-S22; Vol. 32 No.3; CLSI Performance Standards for Antimicrobial Susceptibility Testing; Twenty-Second Informational Supplement. Jan 2012). |
| 2 | NS | Non-susceptible |
A
category
used
for
isolates
for
which
only
a
susceptible
interpretive
criterion
has
been
designated
because
of
the
absence
or
rare
occurrence
of
resistant
strains.
Isolates
that
have
MICs
above
or
zone
diameters
below
the
value
indicated
for
the
susceptible
breakpoint
should
be
reported
as
non-susceptible.
NOTE 1: An isolate that is interpreted as non-susceptible does not necessarily mean that the isolate has a resistance mechanism. It is possible that isolates with MICs above the susceptible breakpoint that lack resistance mechanisms may be encountered within the wild-type distribution subsequent to the time the susceptible-only breakpoint is set. NOTE 2: For strains yielding results in the "nonsusceptible" category, organism identification and antimicrobial susceptibility test results should be confirmed. Synonym: decreased susceptibility. |
| 2 | R | Resistant |
Bacterial
strain
inhibited
in
vitro
by
a
concentration
of
an
antimicrobial
agent
that
is
associated
with
a
high
likelihood
of
therapeutic
failure.
Reference:
CLSI
(http://www.clsi.org/Content/NavigationMenu/Resources/HarmonizedTerminologyDatabase/Harmonized_Terminolo.htm)
Projects:
ISO
20776-1,
ISO
20776-2
[Note 1: Bacterial strains are categorized as resistant by applying the appropriate breakpoints in a defined phenotypic test system.] [Note 2: This breakpoint can be altered due to changes in circumstances (e.g., changes in commonly used drug dosages, emergence of new resistance mechanisms).] |
| 3 | SYN-R | Synergy - resistant |
A
category
for
isolates
where
the
bacteria
(e.g.
enterococci)
are
not
susceptible
in
vitro
to
a
combination
therapy
(e.g.,
high-level
aminoglycoside
and
cell
wall
active
agent).
This
is
predictive
that
this
combination
therapy
will
not
be
effective.
Usage Note: Since the use of penicillin or ampicillin alone often results in treatment failure of serious enterococcal or other bacterial infections, combination therapy is usually indicated to enhance bactericidal activity. The synergy between a cell wall active agent (such as penicillin, ampicillin, or vancomycin) and an aminoglycoside (such as gentamicin, kanamycin or streptomycin) is best predicted by screening for high-level bacterial resistance to the aminoglycoside. Open Issue: The print name of the code is very general and the description is very specific to a pair of classes of agents, which may lead to confusion of these concepts in the future should other synergies be found. |
| 2 | S | Susceptible |
Bacterial
strain
inhibited
by
in
vitro
concentration
of
an
antimicrobial
agent
that
is
associated
with
a
high
likelihood
of
therapeutic
success.
Reference:
CLSI
(http://www.clsi.org/Content/NavigationMenu/Resources/HarmonizedTerminologyDatabase/Harmonized_Terminolo.htm)
Synonym
(earlier
term):
Sensitive
Projects:
ISO
20776-1,
ISO
20776-2
[Note 1: Bacterial strains are categorized as susceptible by applying the appropriate breakpoints in a defined phenotypic system.] [Note 2: This breakpoint can be altered due to changes in circumstances (e.g., changes in commonly used drug dosages, emergence of new resistance mechanisms).] |
| 3 | SDD | Susceptible-dose dependent |
A
category
that
includes
isolates
with
antimicrobial
agent
minimum
inhibitory
concentrations
(MICs)
that
approach
usually
attainable
blood
and
tissue
levels
and
for
which
response
rates
may
be
lower
than
for
susceptible
isolates.
Reference: CLSI document M44-A2 2009 "Method for antifungal disk diffusion susceptibility testing of yeasts; approved guideline - second edition" - page 2. |
| 3 | SYN-S | Synergy - susceptible |
A
category
for
isolates
where
the
bacteria
(e.g.
enterococci)
are
susceptible
in
vitro
to
a
combination
therapy
(e.g.,
high-level
aminoglycoside
and
cell
wall
active
agent).
This
is
predictive
that
this
combination
therapy
will
be
effective.
Usage Note: Since the use of penicillin or ampicillin alone often results in treatment failure of serious enterococcal or other bacterial infections, combination therapy is usually indicated to enhance bactericidal activity. The synergy between a cell wall active agent (such as penicillin, ampicillin, or vancomycin) and an aminoglycoside (such as gentamicin, kanamycin or streptomycin) is best predicted by screening for high-level bacterial resistance to the aminoglycoside. Open Issue: The print name of the code is very general and the description is very specific to a pair of classes of agents, which may lead to confusion of these concepts in the future should other synergies be found. |
| 2 | VS Deprecated | very susceptible |
The
patient
is
considered
as
carrier
based
on
the
testing
results.
A
carrier
is
an
individual
who
carries
an
altered
form
of
a
gene
which
can
lead
to
having
a
child
or
offspring
in
future
generations
with
a
genetic
disorder.
Deprecation Comment: This antimicrobial susceptibility test interpretation concept is recommended by OO to be deprecated as it is no longer recommended for use in susceptibility testing by CLSI (reference CLSI document M100-S22; Vol. 32 No.3; CLSI Performance Standards for Antimicrobial Susceptibility Testing; Twenty-Second Informational Supplement. Jan 2012). |
| 1 | EX | outside threshold |
The
observation/test
result
is
interpreted
as
being
outside
the
inclusion
range
for
a
particular
protocol
within
which
the
result
is
being
reported.
Example: A positive result on a Hepatitis screening test. Open Issue: EX, HX, LX: These three concepts do not seem to meet a clear need in the vocabulary, and their use in observation interpretation appears likely to be covered by other existing concepts (e.g., A, H, L). The only apparent significant difference is their reference to use in protocols for exclusion of study subjects. These concepts/codes were proposed by RCRIM for use in the CTLaboratory message. They were submitted and approved in the November 2005 Harmonization cycle in proposal "030103C_VOCAB_RCRIM_l_quade_RCRIM Obs Interp_20051028154455". However, this proposal was not fully implemented in the vocabulary. The proposal recommended creation of the x_ClinicalResearchExclusion domain in ObservationInterpretation with a value set including those three concepts/codes, but there is no subdomain of that name or equivalent with a binding to either of the value sets that contain these concepts/codes. Members of the OO WG have recently attempted to contact members of RCRIM regarding these concepts, both by email and at the recent WGM in Atlanta, without response. It is felt by OO that the best course of action to take at this time is to add this comprehensive Open Issue rather than deprecate these three concepts at this time, until further discussion is held. |
| 2 | HX | above high threshold |
The
observation/test
result
is
interpreted
as
being
outside
the
inclusion
range
for
a
particular
protocol
within
which
the
result
is
being
reported.
Example: A positive result on a Hepatitis screening test. Open Issue: EX, HX, LX: These three concepts do not seem to meet a clear need in the vocabulary, and their use in observation interpretation appears likely to be covered by other existing concepts (e.g., A, H, L). The only apparent significant difference is their reference to use in protocols for exclusion of study subjects. These concepts/codes were proposed by RCRIM for use in the CTLaboratory message. They were submitted and approved in the November 2005 Harmonization cycle in proposal "030103C_VOCAB_RCRIM_l_quade_RCRIM Obs Interp_20051028154455". However, this proposal was not fully implemented in the vocabulary. The proposal recommended creation of the x_ClinicalResearchExclusion domain in ObservationInterpretation with a value set including those three concepts/codes, but there is no subdomain of that name or equivalent with a binding to either of the value sets that contain these concepts/codes. Members of the OO WG have recently attempted to contact members of RCRIM regarding these concepts, both by email and at the recent WGM in Atlanta, without response. It is felt by OO that the best course of action to take at this time is to add this comprehensive Open Issue rather than deprecate these three concepts at this time, until further discussion is held. |
| 2 | LX | below low threshold |
The
numeric
observation/test
result
is
interpreted
as
being
below
the
low
threshold
value
for
a
particular
protocol
within
which
the
result
is
being
reported.
Example: A Total White Blood Cell Count falling below a protocol-defined threshold value of 3000/mm^3 Open Issue: EX, HX, LX: These three concepts do not seem to meet a clear need in the vocabulary, and their use in observation interpretation appears likely to be covered by other existing concepts (e.g., A, H, L). The only apparent significant difference is their reference to use in protocols for exclusion of study subjects. These concepts/codes were proposed by RCRIM for use in the CTLaboratory message. They were submitted and approved in the November 2005 Harmonization cycle in proposal "030103C_VOCAB_RCRIM_l_quade_RCRIM Obs Interp_20051028154455". However, this proposal was not fully implemented in the vocabulary. The proposal recommended creation of the x_ClinicalResearchExclusion domain in ObservationInterpretation with a value set including those three concepts/codes, but there is no subdomain of that name or equivalent with a binding to either of the value sets that contain these concepts/codes. Members of the OO WG have recently attempted to contact members of RCRIM regarding these concepts, both by email and at the recent WGM in Atlanta, without response. It is felt by OO that the best course of action to take at this time is to add this comprehensive Open Issue rather than deprecate these three concepts at this time, until further discussion is held. |
| 1 | HM Deprecated | Hold for Medical Review |
Hold
for
Medical
Review
Usage Note: This code is not intended for use in V3 artifacts. It is included in the code system to maintain alignment with the V2 Table 0078 "Interpretation Codes." |
| 1 | (ObservationInterpretationDetection) Abstract |
Interpretations
of
the
presence
or
absence
of
a
component
/
analyte
or
organism
in
a
test
or
of
a
sign
in
a
clinical
observation.
In
keeping
with
laboratory
data
processing
practice,
these
concepts
provide
a
categorical
interpretation
of
the
"meaning"
of
the
quantitative
value
for
the
same
observation.
|
|
| 2 | IND | Indeterminate |
The
specified
component
/
analyte,
organism
or
clinical
sign
could
neither
be
declared
positive
/
negative
nor
detected
/
not
detected
by
the
performed
test
or
procedure.
Usage Note: For example, if the specimen was degraded, poorly processed, or was missing the required anatomic structures, then "indeterminate" (i.e. "cannot be determined") is the appropriate response, not "equivocal". |
| 3 | E | Equivocal |
The
test
or
procedure
was
successfully
performed,
but
the
results
are
borderline
and
can
neither
be
declared
positive
/
negative
nor
detected
/
not
detected
according
to
the
current
established
criteria.
|
| 2 | NEG | Negative |
An
absence
finding
of
the
specified
component
/
analyte,
organism
or
clinical
sign
based
on
the
established
threshold
of
the
performed
test
or
procedure.
[Note: Negative does not necessarily imply the complete absence of the specified item.] |
| 3 | ND | Not detected |
The
presence
of
the
specified
component
/
analyte,
organism
or
clinical
sign
could
not
be
determined
within
the
limit
of
detection
of
the
performed
test
or
procedure.
|
| 2 | POS | Positive |
A
presence
finding
of
the
specified
component
/
analyte,
organism
or
clinical
sign
based
on
the
established
threshold
of
the
performed
test
or
procedure.
|
| 3 | DET | Detected |
The
measurement
of
the
specified
component
/
analyte,
organism
or
clinical
sign
above
the
limit
of
detection
of
the
performed
test
or
procedure.
|
| 1 | (ObservationInterpretationExpectation) Abstract |
Interpretation
of
the
observed
result
taking
into
account
additional
information
(contraindicators)
about
the
patient's
situation.
Concepts
in
this
category
are
mutually
exclusive,
i.e.,
at
most
one
is
allowed.
|
|
| 2 | EXP | Expected |
This
result
has
been
evaluated
in
light
of
known
contraindicators.
Once
those
contraindicators
have
been
taken
into
account
the
result
is
determined
to
be
"Expected"
(e.g.,
presence
of
drugs
in
a
patient
that
is
taking
prescription
medication
for
pain
management).
|
| 2 | UNE | Unexpected |
This
result
has
been
evaluated
in
light
of
known
contraindicators.
Once
those
contraindicators
have
been
taken
into
account
the
result
is
determined
to
be
"Unexpected"
(e.g.,
presence
of
non-prescribed
drugs
in
a
patient
that
is
taking
prescription
medication
for
pain
management).
|
| 1 | OBX Deprecated | Interpretation qualifiers in separate OBX segments |
Interpretation
qualifiers
in
separate
OBX
segments
Usage Note: This code is not intended for use in V3 artifacts. It is included in the code system to maintain alignment with the V2 Table 0078 "Interpretation Codes." |
| 1 | (ReactivityObservationInterpretation) Abstract |
Interpretations
of
the
presence
and
level
of
reactivity
of
the
specified
component
/
analyte
with
the
reagent
in
the
performed
laboratory
test.
|
|
| 2 | NR | Non-reactive |
An
absence
finding
used
to
indicate
that
the
specified
component
/
analyte
did
not
react
measurably
with
the
reagent.
|
| 2 | RR | Reactive |
A
presence
finding
used
to
indicate
that
the
specified
component
/
analyte
reacted
with
the
reagent
above
the
reliably
measurable
limit
of
the
performed
test.
|
| 3 | WR | Weakly reactive |
A
weighted
presence
finding
used
to
indicate
that
the
specified
component
/
analyte
reacted
with
the
reagent,
but
below
the
reliably
measurable
limit
of
the
performed
test.
|